PT Mobile Logo

Search form


Psychiatric Epigenetics: A Key to the Molecular Basis of and Therapy for Psychiatric Disorders: Page 3 of 3

Psychiatric Epigenetics: A Key to the Molecular Basis of and Therapy for Psychiatric Disorders: Page 3 of 3

Table 1: Some important enzymes involved in epigenetic modificationsTable 1: Some important enzymes involved in epigenetic modifications
Table 2: Examples of known epigenetic modifiers with therapeutic implications orTable 2: Examples of known epigenetic modifiers with therapeutic impli...
Table 3: Epigenetic aberrations reported in psychiatric diseaseTable 3: Epigenetic aberrations reported in psychiatric disease

DNA interference

Non-coding RNAs, such as microRNAs (miRNAs), which are 20 to 25 bases in length, are another important feature of epigenetic regulation. In general, miRNAs bind to target messenger RNAs (mRNAs) and inhibit the translation or degrade mRNAs and prevent protein synthesis. Remarkably, each gene can be targeted by multiple miRNAs and each miRNA (approximately 1000 known) may target hundreds of mRNAs. In addition to intracellular regulation of gene expression, miRNAs can affect the expression of various genes (eg, metabolic genes) far from the locations from which they were generated in the form of circulating miRNAs.

A number of studies have uncovered close to 2 dozen miRNAs affected in psychiatric disorders (Table 3). A microarray analysis showed decreased expression of 16 miRNAs in the frontal lobe of postmortem brains in patients with schizophrenia and schizoaffective disorder.14 The assay included miR-24, miR-26b, miR-30e, and miR-92, and results were confirmed by quantitative real-time polymerase chain reaction analysis.

Increased miRNA biogenesis in the superior temporal gyrus and dorsolateral prefrontal cortex and overexpression of miR-15a, miR-15b, miR-195, and miR-107 were also found in patients with schizophrenia. These miRNAs have the capacity to regulate the expression of target genes, including ATXN2, BDNF, CHRM1, DRD1, GABR1, GRIN1, GRM7, HTR4, NRG1, and RELN, which are known to be affected in schizophrenia.15 Overexpression of miR-181b was found to be associated with reduced expression of VSNL1 (which regulates the activity of adenylyl cyclase) and GRIA2 (glutamate receptor, ionotropic, AMPA 2) in the gray matter of the temporal cortex in postmortem brain samples of patients with schizophrenia. Subsequent studies verified that the expression of VSNL1 and GRIA2 is suppressed by synthetic miR-181b in cell culture experiments.16

Other targets of miR-181b are genes coding receptors for GABA (GABRA1), glutamate (GRID, GRIK2, GRM5, and GRM7), or serotonin (HTR1B and HTR2C), which contribute to the pathogenesis of mental diseases. GRID1 and miR-346, which are localized to the intron 2 of GRID1, exhibited reduced expression in postmortem brain samples of patients with schizophrenia.17

Recent findings suggest an increased expression of exosomal miR-497 and miR-29c in the postmortem prefrontal cortices of patients with schizophrenia and bipolar disorder, respectively, and a decrease in circulating miR-134 in the plasma of drug-free patients in the manic phase of bipolar disorder.18,19

Collectively, the progress made in miRNA studies not only indicates that these non-coding regulatory RNAs may contribute to the pathogenesis of psychiatric diseases and mediate the effects of mood stabilizers but also suggests the potential use of circulating miRNAs as diagnostic biomarkers and the use of synthetic miRNAs (that mimic the activity of circulating or brain specific miRNAs) as therapeutic tools.

Conclusion and perspectives

The major challenges for epigenetic therapies are target specificity of the drugs—an issue that is also true for most of the currently used drugs in medicine, especially in psychiatry. Recent discoveries on the use of zinc finger proteins and other tools such as TALEN (transcription activator-like effector nucleases) that recognize specific DNA sequences have paved the way for the recruitment of regulatory proteins, enzymes, and drugs to gene promoters for site-specific epigenetic modifications.20 However, the mechanisms that deliver the modifiers to specific neuronal nuclei or pathways are still to be identified.

Concurrent activation of a desired pathway using transcranial magnetic stimulation (TMS) or other tools may help to deliver the specific epigenetic modifiers to the activated pathways or neuronal nuclei by the mediation of glucose or other molecules that are utilized at a higher rate by the activated cells. Given that electroconvulsive therapy–induced neuronal activity is a powerful epigenetic modifier in the adult brain and that the abnormal epigenomic brain map for psychiatric disorders is under development, epigenetic modifications of specific brain regions using noninvasive methods such as TMS may be among the epigenetic therapies coming over the horizon.21



Dr Abdolmaleky is a Visiting Professor/Research Associate in the departments of medicine and genetics and genomics at Boston University School of Medicine, and Research Associate at the Harvard Institute of Psychiatric Epidemiology and Genetics in Boston. Dr Shafa is Scientific Director at Metrowest CNS Research Center, Pharmacogenomics, in Natick, Mass. Dr Tsuang is Distinguished Professor of Psychiatry and Behavioral Genomics Endowed Chair and Director, Center for Behavioral Genomics, department of psychiatry, University of California, San Diego. Dr Tsuang is also Director of the Harvard Institute of Psychiatric Epidemiology and Genetics, Boston. Dr Thiagalingam is an Associate Professor in the departments of medicine, genetics and genomics, and pathology and laboratory medicine at Boston University School of Medicine. The authors report no conflicts of interest concerning the subject matter of this article.


1. Hamshere ML, Walters JT, Smith R, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2012 May 22; [Epub ahead of print].

2. Dong E, Gavin DP, Chen Y, Davis J. Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Transl Psychiatry. 2012;2:e159.

3. Gavin DP, Sharma RP, Chase KA, et al. Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis [published correction appears in Neuropsychopharmacology. 2012;37:2173]. Neuropsychopharmacology. 2012;37:531-542.

4. Yang BZ, Zhang H, Ge W, et al. Child abuse and epigenetic mechanisms of disease risk. Am J Prev Med. 2013;44:101-107.

5. Dempster EL, Pidsley R, Schalkwyk LC, et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011;20:4786-4796.

6. Abdolmaleky HM, Zhou JR, Thiagalingam S, Smith CL. Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics. Pharmacogenomics. 2008;9:1809-1823.

7. Abdolmaleky HM, Yaqubi S, Papageorgis P, et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr Res. 2011;129:183-190.

8. Nishioka M, Bundo M, Koike S, et al. Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode schizophrenia. J Hum Genet. 2013;58:91-97.

9. Melas PA, Rogdaki M, Ösby U, et al. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 2012;26:2712-2718.

10. Lott SA, Burghardt PR, Burghardt KJ, et al. The influence of metabolic syndrome, physical activity and genotype on catechol-O-methyl transferase promoter-region methylation in schizophrenia. Pharmacogenomics J. 2012 Mar 6; [Epub ahead of print].

11. Kwon B, Houpt TA. Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. Brain Res. 2010;1333:36-47.

12. Calabrese F, Luoni A, Guidotti G, et al. Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid. Psychopharmacology (Berl). 2013;226:101-112.

13. Sanjana NE, Levanon EY, Hueske EA, et al. Activity-dependent A-to-I RNA editing in rat cortical neurons. Genetics. 2012;192:281-287.

14. Perkins DO, Jeffries CD, Jarskog LF, et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol. 2007;8:R27.

15. Beveridge NJ, Gardiner E, Carroll AP, et al. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry. 2010;15:1176-1189.

16. Beveridge NJ, Tooney PA, Carroll AP, et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008;17:1156-1168.

17. Zhu Y, Kalbfleisch T, Brennan MD, Li Y. A microRNA gene is hosted in an intron of a schizophrenia-susceptibility gene. Schizophr Res. 2009;109:86-89.

18. Banigan MG, Kao PF, Kozubek JA, et al. Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLoS One. 2013;8:e48814.

19. Rong H, Liu TB, Yang KJ, et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res. 2011;45:92-95.

20. Sanjana NE, Cong L, Zhou Y, et al. A transcription activator-like effector toolbox for genome engineering. Nat Protoc. 2012;7:171-192.

21. Guo JU, Ma DK, Mo H, et al. Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci. 2011;14:1345-1351.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.